A Phase 2 interventional study of ACE-011 and Placebo in Multiple Myeloma, sponsored by Celgene. Completed at 2 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 84th largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2008, is one of 24 in phase 2, and was the 25th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 38 · Phase 3 32
First in 2001; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 83 across the 108 interventional studies, 355 across the 35 observational. Of the 120 that completed or were terminated, 43 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
6 of the studies in Multiple Myeloma by Bristol-Myers Squibb that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03989414CelgeneA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | 2026-11-30 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection on days 1, 29, 57 and 85.
Biological: Placebo
Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
Biological: ACE-011
Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
Biological: ACE-011
Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
Biological: ACE-011
ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
Also known as: hActRIIA-IgG1
Placebo given by the subcutaneous route of administration monthly for 4 doses.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A treatment emergent adverse event (TEAE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causality assessment. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported.
Time frame: From first dose to termination visit on Day 169
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
A treatment emergent adverse event (TEAE) related to study drug was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that was determined to be related to the study drug. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported. Treatment emergent adverse events were assessed by the investigator as possibly, probably, or definitely related to the study drug.
Time frame: From first dose to termination visit on Day 169
Number of Participants With Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that at any dose (including overdose) that was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in permanent or significant disability/incapacity, or was a congenital anomaly/birth defect. The number of participants with at least one serious adverse event are reported.
Time frame: From first dose up to termination visit on Day 169
Change From Baseline in Hemoglobin
Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.
Time frame: Day 1 (baseline), Day 8, Day 29, Day 36, Day 57, Day 85, Day 113, Day 169
Number of Participants With Electrocardiogram Abnormalities
The number of participants with at least one clinically significant postbaseline electrocardiogram abnormality. The abnormalities included left ventricular hypertrophy, atrial fibrillation, sinus bradycardia, sinus tachycardia, and myocardial ischemia. Data is reported as the cumulative number of participants with abnormalities over the scheduled collection timepoints.
Time frame: Pre-dose, Day 1, Day 92, and Day 169
Number of Participants With Hypertension or Increased Blood Pressure
The number of participants who experienced hypertension or an increase in blood pressure from baseline up to Day 92. Abnormal blood pressure was defined as: * Systolic blood pressure ≤ 90 or ≥ 180 mmHg * Systolic blood pressure change (increase or decrease) ≥ 20 mmHg * Diastolic blood pressure ≤ 60 or ≥ 100 mmHg * Diastolic blood pressure change (increase or decrease) ≥ 15 mmHg
Time frame: From baseline up to Day 92
Number of Participants With Skeletal-related Events (SRE)
Skeletal-related events are defined as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression, within 2 weeks of study enrollment. They are determined by skeletal surveys, including x-rays of the skull, entire spine, pelvis, ribs, humeri, and femora.
Time frame: From first dose up to 2 weeks post first dose
Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)
The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.
Time frame: From baseline (Day 1) to Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
| Milestone | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Started | 6 | 8 | 8 | 8 |
| Completed | 6 | 6 | 7 | 7 |
| Not completed | 0 | 2 | 1 | 1 |
| Withdrew: Investigator's request | 0 | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
A treatment emergent adverse event (TEAE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causality assessment. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported.
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 | 7 | 7 | 8 |
A treatment emergent adverse event (TEAE) related to study drug was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that was determined to be related to the study drug. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported. Treatment emergent adverse events were assessed by the investigator as possibly, probably, or definitely related to the study drug.
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug | 0 | 1 | 0 | 1 |
A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that at any dose (including overdose) that was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in permanent or significant disability/incapacity, or was a congenital anomaly/birth defect. The number of participants with at least one serious adverse event are reported.
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 1 | 0 | 3 |
Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.
| g/dL | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Day 8 | 0.47 ± 0.288 | 0.89 ± 1.254 | 0.83 ± 0.599 | 0.80 ± 0.844 |
| Day 29 | 0.50 ± 0.607 | -0.91 ± 1.844 | 0.66 ± 0.457 | 0.96 ± 1.648 |
| Day 36 | 1.02 ± 0.643 | 0.73 ± 1.873 | 1.00 ± 0.787 | 1.48 ± 1.167 |
| Day 57 | 0.53 ± 0.602 | 0.47 ± 1.682 | 1.09 ± 1.022 | 1.00 ± 1.22 |
| Day 85 | 0.78 ± 0.958 | 0.57 ± 0.907 | 0.86 ± 1.323 | 1.56 ± 0.704 |
| Day 113 | 0.33 ± 0.789 | 0.53 ± 1.141 | 0.96 ± 1.620 | 0.97 ± 1.024 |
| Day 169/Early Termination | 0.13 ± 1.140 | 0.57 ± 1.500 | 0.33 ± 1.763 | 0.03 ± 2.392 |
The number of participants with at least one clinically significant postbaseline electrocardiogram abnormality. The abnormalities included left ventricular hypertrophy, atrial fibrillation, sinus bradycardia, sinus tachycardia, and myocardial ischemia. Data is reported as the cumulative number of participants with abnormalities over the scheduled collection timepoints.
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Electrocardiogram Abnormalities | 4 | 2 | 2 | 2 |
The number of participants who experienced hypertension or an increase in blood pressure from baseline up to Day 92. Abnormal blood pressure was defined as: * Systolic blood pressure ≤ 90 or ≥ 180 mmHg * Systolic blood pressure change (increase or decrease) ≥ 20 mmHg * Diastolic blood pressure ≤ 60 or ≥ 100 mmHg * Diastolic blood pressure change (increase or decrease) ≥ 15 mmHg
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Hypertension or Increased Blood Pressure | 0 | 1 | 0 | 2 |
Skeletal-related events are defined as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression, within 2 weeks of study enrollment. They are determined by skeletal surveys, including x-rays of the skull, entire spine, pelvis, ribs, humeri, and femora.
| Participants | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Number of Participants With Skeletal-related Events (SRE) | 0 | 1 | 2 | 2 |
The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.
| Percent change | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 |
|---|---|---|---|---|
| Day 29 | -6.0 ± 12.25 | -9.4 ± 22.60 | -5.8 ± 25.03 | -6.4 ± 23.87 |
| Day 57 | -7.2 ± 6.77 | -8.0 ± 26.09 | -11.0 ± 33.87 | -11.6 ± 26.34 |
| Day 85 | -4.5 ± 3.78 | -12.7 ± 23.08 | -10.5 ± 37.50 | -11.1 ± 28.79 |
| Day 113 | -3.5 ± 4.46 | -13.7 ± 25.03 | -12.3 ± 38.04 | -11.4 ± 29.43 |
| Day 141 | 0.7 ± 13.05 | -13.7 ± 25.26 | -15.0 ± 37.33 | -12.1 ± 32.79 |
| Day 169 | -3.0 ± 7.59 | -14.7 ± 24.59 | -15.0 ± 38.40 | -13.6 ± 30.36 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 10 months). SAEs and Other AEs were assessed from first dose to Day 169.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACE 011 0.1 mg/kg | 1/8 (12.5%) | 1/8 (12.5%) | 7/8 (87.5%) |
| ACE 011 0.3 mg/kg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| ACE 011 0.5 mg/kg | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | ACE 011 0.1 mg/kg | ACE 011 0.3 mg/kg | ACE 011 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/8 | 0/8 | 1/8 | 0/6 |
| Sudden deathGeneral disorders | 1/8 | 0/8 | 0/8 | 0/6 |
| PneumoniaInfections and infestations | 0/8 | 0/8 | 1/8 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 1/8 | 0/6 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 1/8 | 0/6 |
| Event | ACE 011 0.1 mg/kg | ACE 011 0.3 mg/kg | ACE 011 0.5 mg/kg | Placebo |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 6/8 | 6/8 | 4/6 |
| LeukopeniaBlood and lymphatic system disorders | 3/8 | 1/8 | 1/8 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 1/8 | 1/8 | 2/8 | 0/6 |
| GranulocytopeniaBlood and lymphatic system disorders | 2/8 | 1/8 | 1/8 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/8 | 0/8 | 2/8 | 0/6 |
| EosinophiliaBlood and lymphatic system disorders | 0/8 | 0/8 | 0/8 | 1/6 |
| Myocardial ischaemiaCardiac disorders | 0/8 | 0/8 | 0/8 | 1/6 |
| Sinus bradycardiaCardiac disorders | 0/8 | 0/8 | 0/8 | 1/6 |
| FatigueGeneral disorders | 0/8 | 0/8 | 0/8 | 1/6 |
| BronchitisInfections and infestations | 0/8 | 1/8 | 1/8 | 1/6 |
| Age, Continuous(Years) | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 | Total |
|---|---|---|---|---|---|
| Mean | 62.0 ± 7.92 | 60.5 ± 13.28 | 63.6 ± 7.50 | 57.8 ± 12.30 | 60.9 ± 10.42 |
| Sex: Female, Male(Participants) | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 | Total |
|---|---|---|---|---|---|
| Female | 4 | 2 | 5 | 4 | 15 |
| Male | 2 | 6 | 3 | 4 | 15 |
| Race (NIH/OMB)(Participants) | Placebo | 0.1 mg/kg ACE 011 | 0.3 mg/kg ACE 011 | 0.5 mg/kg ACE 011 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 7 | 8 | 8 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Ran from Sep 2008 to primary completion in Aug 2009, 11 months.
Results were first posted in Oct 2024, 15 years 2 months after primary completion. A results delay was requested in Sep 2012.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 11 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept